Cortex reacquires ampakines for respiratory depression from Valeant's Biovail
This article was originally published in Scrip
Executive Summary
Cortex Pharmaceuticals has reacquired certain ampakine assets for potential use in respiratory depression from Valeant's Biovail subsidiary.